Claromer

Claromer is the branded name for a family of synthetic small molecule compounds known as "peptoids," developed by Maxwell Biosciences. These molecules are designed to mimic and improve upon the structure and function of natural immune system peptides—specifically cathelicidin (LL-37)—which play a key role in innate immunity. Claromers act as broad-spectrum anti-infectives with demonstrated preclinical activity against a wide range of pathogens including viruses (such as HSV-1, SARS-CoV-2, Ebola virus), bacteria, fungi, and biofilms. Their mechanism involves direct disruption of pathogen membranes by targeting phosphatidylserine exposed on microbial surfaces but not on healthy human cells. This selectivity allows them to destroy pathogens while sparing beneficial microbiota and healthy tissues. The compounds are stable in vivo, can be manufactured via solid-phase synthesis and purified by HPLC, and have shown no significant toxicity in preclinical models. Maxwell Biosciences is advancing Claromers toward clinical trials for indications such as chronic rhinosinusitis and other infectious diseases[1][2][3][9].

Brand names

Claromer

Other names

peptoid antimicrobialsynthetic peptoid oligomerbiostable peptide analog